Prevymis (letermovir) is a medication used for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult recipients of an allogeneic stem cell transplant [1].
What is Prevymis approved for?
Prevymis is approved for preventing CMV infection and disease in adult patients who have undergone a hematopoietic stem cell transplant [1].
How does Prevymis work?
Letermovir, the active ingredient in Prevymis, works by inhibiting the CMV DNA terminase complex. This action prevents the virus from replicating its DNA [1].
When does Prevymis patent expire?
Information on the specific patent expiry dates for Prevymis is available through resources like DrugPatentWatch.com [2]. Generally, drug patents offer protection for a period, after which generic versions may become available.
What are the risks associated with Prevymis?
The most common side effects reported with Prevymis include diarrhea and nausea [1].
How is Prevymis administered?
Prevymis can be administered intravenously (IV) or orally [1].
Who manufactures Prevymis?
Prevymis is manufactured by Merck & Co. [1].
How does Prevymis compare to other CMV prophylaxis options?
Prevymis offers an alternative mechanism of action compared to older antiviral drugs, which may be beneficial in cases of resistance or for patients who cannot tolerate other treatments [1].
What is the clinical data supporting Prevymis?
Clinical trials have demonstrated that Prevymis is effective in reducing the incidence of clinically significant CMV infection and disease in hematopoietic stem cell transplant recipients [1].
Can Prevymis be used for treatment of active CMV infection?
Prevymis is indicated for prophylaxis, meaning prevention, of CMV infection and disease, not for the treatment of active CMV infection [1].
What are the alternatives to Prevymis for CMV prophylaxis?
Other medications, such as ganciclovir, valganciclovir, and cidofovir, have been used for CMV prophylaxis, although they have different mechanisms of action and side effect profiles [1].
Sources:
1. https://www.prevymis.com/
2. https://www.drugpatentwatch.com/